Recruiting

NCT Number: NCT05638841

Prospective Cohort Study of the Risk of Recurrent Atrial Fibrillation After Radiofrequency Ablation

In this study, the continuous inclusion of atrial fibrillation patients treated by catheter ablation in the Department of Cardiology, Peking University Third Hospital, through the collection of clinical data and outpatient follow-up, to explore the risk factors of atrial fibrillation recurrence after catheter ablation and the influencing factors of major clinical events in atrial fibrillation patients, and further guide the management mode of atrial fibrillation patients.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Atrial Fibrillation Arrhythmias, Cardiac Cardiovascular Diseases Heart Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Peking-University-Third-Hospital

Beijing, China

Location status: Recruiting

Location contact

Pengxin Xie

CONTACT

[email protected]

18810793282

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

1) Age > 18
2) ECG or holter electrocardiogram confirmed atrial fibrillation

Exclusion criteria

1) Hematological diseases, autoimmune diseases and malignant tumors
2) Immobility caused by hemiplegia or severe trauma
3) The expected survival time is less than 2 years
4) Poor compliance and high risk of expected loss of follow-up
5) Disorders of consciousness or Alzheimer's disease

Treatment and study plan

After radiofrequency ablation of atrial fibrillation

Other

This study imposed an intervention. Clinical data were obtained by telephone or outpatient follow-up.

Primary outcomes

Compound cardiovascular event

Time frame: 24 months

Stroke, hemorrhage, re-hospitalization for atrial fibrillation and heart failure, and all-cause death

Study contacts

Contact information is provided by the study sponsor or research team.

Pengxin Xie, master

CONTACT

[email protected]

+8618810793282

Yanguang Li, Doctor

CONTACT

[email protected]

+8613693327068

Sponsors and collaborators

Lead sponsor

Peking University Third Hospital

Other

Registry information

Important dates

Study start: 2023
Primary completion: 2024
Study completion: 2026
First posted: Dec 6, 2022
Registry last updated: Feb 21, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting